Cholinergic

AF710B, now developed by Anavex Life Sciences as ANAVEX3-71, is an experimental drug that acts on two targets at once: it activates the M1 muscarinic acetylcholine receptor from an allosteric site, amplifying acetylcholine's own effect, and it is a sigma-1 receptor agonist. In Alzheimer's-model mice and rats, doses of 10 µg/kg a day improved memory and reduced amyloid, tau phosphorylation and glial inflammation, and in rats the benefits outlasted the end of treatment by weeks. In people it has been through a single-dose phase 1 study and a 71-person phase 2 trial in schizophrenia that met its safety endpoint but released no symptom or cognition results.

Alpha-GPC (choline alfoscerate) is a choline-containing phospholipid breakdown product, sold as a prescription drug in some countries and a supplement elsewhere. It is a precursor of both choline and acetylcholine. Its record is unusually mixed. One very large Korean cohort linked it to lower dementia conversion, while another linked it to higher 10-year stroke risk.

Aniracetam is a fat-soluble piracetam analog that positively modulates AMPA glutamate receptors. It was marketed in Italy and Japan for dementia and post-stroke cognitive symptoms, and placebo-controlled trials in Alzheimer-type dementia gave contradictory answers. It is no longer in clinical use, and in healthy animals it does nothing measurable.

Citicoline (CDP-choline) is an intermediate in the synthesis of phosphatidylcholine, the main phospholipid in cell membranes. It is a prescription drug in some countries and a supplement in others. A meta-analysis found it improved cognitive status in mild cognitive impairment, Alzheimer's disease and post-stroke dementia, though the underlying studies were of poor quality.

Coluracetam, originally MKC-231, is the one racetam with a genuinely distinct mechanism: it enhances high-affinity choline uptake by acting on the choline transporter CHT1 itself. Everything known about it comes from rodents with chemically lesioned cholinergic neurons. No human trial with a published abstract is cited here.

Fasoracetam is a racetam repurposed as a metabotropic glutamate receptor activator and trialed in adolescents with ADHD who carry disruptive variants in mGluR network genes. A 30-patient open-label dose-escalation study with one single-blind placebo week reported significant improvement on global rating scales and good tolerability. That is a phase I result and the only human efficacy evidence there is.

Nefiracetam is a Japanese piracetam derivative that potentiates nicotinic α4β2 and NMDA receptors at nanomolar concentrations, through Gs proteins and protein kinase C. Its human testing went in an unexpected direction — post-stroke depression and apathy rather than memory — and the results were mixed at best: no overall antidepressant effect in 159 patients, a positive apathy signal in one trial and nothing in a second that could only randomize 13.

Oxiracetam is the 4-hydroxy analog of piracetam, prescribed for decades in Italy and South Korea for cognitive impairment. Small trials from the late 1980s and early 1990s reported benefit in mild dementia, but a 500-patient trial published in 2026 found no effect whatsoever on post-stroke cognition. South Korea's regulator recommended suspending prescriptions in January 2023.

Piracetam is the original "nootropic". C. Giurgea developed it in the late 1960s and coined the word to describe it. It is licensed in several countries for cognitive disorders, vertigo and cortical myoclonus. The evidence is mixed. An older meta-analysis found a global benefit in older adults with cognitive impairment, but a 2024 meta-analysis could not confirm an effect on memory.

Pramiracetam is a Parke-Davis piracetam derivative with a basic diisopropylaminoethyl side chain, far more potent than piracetam in animal amnesia models. Its two positive controlled human results are narrow: partial reversal of scopolamine-induced amnesia in healthy volunteers and improved delayed recall in young men with memory problems after head injury or anoxia. In Alzheimer's disease it did nothing.

Tropisetron is a prescription 5-HT3 receptor antagonist used as an antiemetic and a partial agonist at α7 nicotinic acetylcholine receptors. Small adjunctive trials in schizophrenia reported better auditory P50 sensory gating and selected attention or memory measures after 1 day to 8 weeks, usually in nonsmokers taking risperidone. Those studies do not establish it as a general cognitive enhancer.

Uridine monophosphate (UMP) is a nucleotide and dietary source of uridine, one of the precursors used to make phosphatidylcholine and other neuronal membrane phospholipids. In rodents, UMP raises brain phosphatides and can increase striatal acetylcholine release; after six weeks it also increased potassium-evoked, but not basal, striatal dopamine release in aged rats. Human cognitive evidence does not isolate UMP: the trials used it inside a multinutrient drink with choline, DHA, EPA, phospholipids, vitamins and selenium, and the primary cognitive outcomes were mixed.